IL235901A0 - Aztidine and piperidine compounds are useful as pde10 inhibitors - Google Patents
Aztidine and piperidine compounds are useful as pde10 inhibitorsInfo
- Publication number
- IL235901A0 IL235901A0 IL235901A IL23590114A IL235901A0 IL 235901 A0 IL235901 A0 IL 235901A0 IL 235901 A IL235901 A IL 235901A IL 23590114 A IL23590114 A IL 23590114A IL 235901 A0 IL235901 A0 IL 235901A0
- Authority
- IL
- Israel
- Prior art keywords
- azetidine
- compounds useful
- piperidine compounds
- pde10 inhibitors
- pde10
- Prior art date
Links
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659911P | 2012-06-14 | 2012-06-14 | |
| PCT/US2013/045768 WO2013188724A1 (en) | 2012-06-14 | 2013-06-14 | Azetidine and piperidine compounds useful as pde10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL235901A0 true IL235901A0 (en) | 2015-09-24 |
Family
ID=48692687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235901A IL235901A0 (en) | 2012-06-14 | 2014-11-25 | Aztidine and piperidine compounds are useful as pde10 inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8691986B2 (enExample) |
| EP (1) | EP2864317A1 (enExample) |
| JP (1) | JP2015519402A (enExample) |
| KR (1) | KR20150023417A (enExample) |
| CN (1) | CN104619694A (enExample) |
| AP (1) | AP2014008136A0 (enExample) |
| AR (1) | AR091436A1 (enExample) |
| AU (1) | AU2013274153B2 (enExample) |
| BR (1) | BR112014031368A2 (enExample) |
| CA (1) | CA2875802A1 (enExample) |
| CL (1) | CL2014003391A1 (enExample) |
| CO (1) | CO7160011A2 (enExample) |
| CR (1) | CR20150012A (enExample) |
| EA (1) | EA201590014A1 (enExample) |
| HK (1) | HK1203935A1 (enExample) |
| IL (1) | IL235901A0 (enExample) |
| MA (1) | MA37748B1 (enExample) |
| MX (1) | MX2014014924A (enExample) |
| PE (1) | PE20150348A1 (enExample) |
| PH (1) | PH12014502780A1 (enExample) |
| SG (1) | SG11201408168UA (enExample) |
| TN (1) | TN2014000510A1 (enExample) |
| TW (1) | TWI508959B (enExample) |
| UY (1) | UY34858A (enExample) |
| WO (1) | WO2013188724A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012013130A (es) | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| UY34858A (es) * | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US8497265B2 (en) * | 2010-05-13 | 2013-07-30 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
| MX2012013130A (es) * | 2010-05-13 | 2013-04-11 | Amgen Inc | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10. |
| MX2012013128A (es) * | 2010-05-13 | 2013-03-20 | Amgen Inc | Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10. |
| WO2011143366A1 (en) * | 2010-05-13 | 2011-11-17 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as pde10 inhibitors |
| UY34858A (es) * | 2012-06-14 | 2013-11-29 | Amgen Inc | Compuestos de azetidina y piperidina útiles como inhibidores de pde10 |
-
2013
- 2013-06-13 UY UY0001034858A patent/UY34858A/es not_active Application Discontinuation
- 2013-06-13 AR ARP130102085 patent/AR091436A1/es unknown
- 2013-06-14 HK HK15104351.8A patent/HK1203935A1/xx unknown
- 2013-06-14 US US13/917,699 patent/US8691986B2/en active Active
- 2013-06-14 SG SG11201408168UA patent/SG11201408168UA/en unknown
- 2013-06-14 CA CA2875802A patent/CA2875802A1/en not_active Abandoned
- 2013-06-14 JP JP2015517445A patent/JP2015519402A/ja active Pending
- 2013-06-14 EA EA201590014A patent/EA201590014A1/ru unknown
- 2013-06-14 KR KR1020147035700A patent/KR20150023417A/ko not_active Withdrawn
- 2013-06-14 MA MA37748A patent/MA37748B1/fr unknown
- 2013-06-14 AU AU2013274153A patent/AU2013274153B2/en not_active Expired - Fee Related
- 2013-06-14 BR BR112014031368A patent/BR112014031368A2/pt not_active IP Right Cessation
- 2013-06-14 MX MX2014014924A patent/MX2014014924A/es unknown
- 2013-06-14 EP EP13731237.7A patent/EP2864317A1/en not_active Withdrawn
- 2013-06-14 PE PE2014002438A patent/PE20150348A1/es not_active Application Discontinuation
- 2013-06-14 CN CN201380031076.4A patent/CN104619694A/zh active Pending
- 2013-06-14 AP AP2014008136A patent/AP2014008136A0/xx unknown
- 2013-06-14 WO PCT/US2013/045768 patent/WO2013188724A1/en not_active Ceased
- 2013-06-14 TW TW102121229A patent/TWI508959B/zh not_active IP Right Cessation
-
2014
- 2014-01-31 US US14/170,146 patent/US9303028B2/en active Active
- 2014-11-25 IL IL235901A patent/IL235901A0/en not_active IP Right Cessation
- 2014-12-04 TN TN2014000510A patent/TN2014000510A1/fr unknown
- 2014-12-11 PH PH12014502780A patent/PH12014502780A1/en unknown
- 2014-12-12 CL CL2014003391A patent/CL2014003391A1/es unknown
-
2015
- 2015-01-08 CO CO15003862A patent/CO7160011A2/es unknown
- 2015-01-13 CR CR20150012A patent/CR20150012A/es unknown
-
2016
- 2016-03-01 US US15/058,023 patent/US9493459B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014014924A (es) | 2015-03-09 |
| MA37748A1 (fr) | 2016-11-30 |
| CO7160011A2 (es) | 2015-01-15 |
| PH12014502780A1 (en) | 2015-02-02 |
| EA201590014A1 (ru) | 2015-04-30 |
| JP2015519402A (ja) | 2015-07-09 |
| AR091436A1 (es) | 2015-02-04 |
| US9303028B2 (en) | 2016-04-05 |
| CA2875802A1 (en) | 2013-12-19 |
| PE20150348A1 (es) | 2015-03-04 |
| WO2013188724A1 (en) | 2013-12-19 |
| US9493459B2 (en) | 2016-11-15 |
| HK1203935A1 (en) | 2015-11-06 |
| US8691986B2 (en) | 2014-04-08 |
| US20160176874A1 (en) | 2016-06-23 |
| AU2013274153B2 (en) | 2016-05-19 |
| TN2014000510A1 (en) | 2016-03-30 |
| US20140148435A1 (en) | 2014-05-29 |
| US20130338138A1 (en) | 2013-12-19 |
| SG11201408168UA (en) | 2015-01-29 |
| BR112014031368A2 (pt) | 2017-06-27 |
| EP2864317A1 (en) | 2015-04-29 |
| TWI508959B (zh) | 2015-11-21 |
| AP2014008136A0 (en) | 2014-12-31 |
| CR20150012A (es) | 2015-02-11 |
| AU2013274153A1 (en) | 2014-12-18 |
| KR20150023417A (ko) | 2015-03-05 |
| MA37748B1 (fr) | 2017-07-31 |
| CN104619694A (zh) | 2015-05-13 |
| TW201412729A (zh) | 2014-04-01 |
| UY34858A (es) | 2013-11-29 |
| CL2014003391A1 (es) | 2015-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180552T1 (hr) | Derivati piperidin-4-il azetidina kao inhibitori jak1 | |
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| LT2920149T (lt) | 3-aminocikloalkilo junginiai, kaip ror-gama-t inhibitoriai, ir jų panaudojimas | |
| IL239212A0 (en) | Inhibitors in the cell - lactamase | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| AP2014007980A0 (en) | Heterobicyclic compounds as beta-lactamase inhibitors | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| ZA201406225B (en) | Thiadiazolidinediones as gsk-3 inhibitors | |
| SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
| PL2912021T3 (pl) | Inhibitory agrekanazy | |
| EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| IL235901A0 (en) | Aztidine and piperidine compounds are useful as pde10 inhibitors | |
| GB201120494D0 (en) | Modified exonuclease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |